Deutsche Bank’s Scinai Immunotherapeutics SCNI Stock Holding History

Deutsche Bank’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-3	Closed	-$13K	–	4511
2020 Q3	$13K	Buy	+3	New	+$11.5K	﹤0.01%	4168
2020 Q1	–	Sell	-2	Closed	-$1K	–	4759
2019 Q4	$1K	Sell	2 -3	-60%	-$1.84K	﹤0.01%	4927
2019 Q3	$2K	Buy	+5	New	+$2.96K	﹤0.01%	4779
2019 Q2	–	Sell	-1	Closed	–	–	5485
2019 Q1	$0	Buy	+1	New	+$520	﹤0.01%	5399
2018 Q4	–	Sell	-26	Closed	-$15K	–	5381
2018 Q3	$15K	Sell	26 -40	-61%	-$23.9K	﹤0.01%	5004
2018 Q2	$44K	Sell	66 -36	-35%	-$23.3K	﹤0.01%	4823
2018 Q1	$55K	Sell	102 -257	-72%	-$160K	﹤0.01%	4725
2017 Q4	$192K	Buy	359 +90	+33%	+$56.6K	﹤0.01%	4049
2017 Q3	$192K	Buy	269 +263	+4,383%	+$216K	﹤0.01%	3904
2017 Q2	$5K	Sell	6 -3	-33%	-$2.21K	﹤0.01%	4753
2017 Q1	$5K	Buy	+9	New	+$4.64K	﹤0.01%	4708

Other funds holding SCNI

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

NFG

Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

GRP

Global Retirement Partners San Rafael, California $5.64B AUM

Deutsche Bank's SCNI Position: Q4 2020 in Review

Deutsche Bank sold out of Scinai Immunotherapeutics (SCNI) in Q4 2020, closing a stake of 3 shares — an estimated $13K sold.

Deutsche Bank first reported a position in SCNI in Q1 2017 and held it in 11 quarters. The position peaked at $192K in Q4 2017. 13 funds tracked by Wall St. Rank hold SCNI as of Q4 2020.

Deutsche Bank reported no remaining Scinai Immunotherapeutics position as of Q4 2020 after selling out during the quarter.
Deutsche Bank sold 3 Scinai Immunotherapeutics shares in Q4 2020, an estimated $13K.
Deutsche Bank first reported a position in Scinai Immunotherapeutics in Q1 2017 and held it in 11 quarters.
Deutsche Bank's Scinai Immunotherapeutics position peaked at $192K in Q4 2017.
13 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q4 2020.

Based on Deutsche Bank's 13F filing for Q4 2020, filed 16 Feb 2021.